

INDEX



IDX

A

- absorption, distribution, metabolism, and elimination (ADME) of drugs, 23
 - structure activity relationships and, 399–404
- acceptors, hydrogen bond, 37–38, 53, 230–231
- acebutolol, 461–462
- acetaminophen, 336–337
 - glucuronic acid conjugation, 359
 - glutathione conjugation, 369
 - sulfate conjugation, 362
- acetazolamide, 421
- acetic acid, 174, 190
- acetoexamide, 354
- acetylation, 369–372
- acetylcholine
 - conformational isomers, 290–291, 294, 296
 - functional group characteristics, 26
 - homologation and, 425–426
 - metabolism alteration, 43–44
 - selectivity, 41
- acetylcholinesterase, 216–217
- acetyl CoA, 369–372
- acetyl groups, 214
- acidic functional groups, 67, 110–112, 474
 - β -dicarbonyl groups, 69–71
 - carboxylic acids, 68–69
 - defined, 68
 - phenols, 75–77
 - sulfates, phosphates, and phosphonates, 78–79
 - sulfonamides and sulfonyleureas, 71–74
 - tetrazoles, 74–75
 - thiols, 77–78
- acids. *See also* bases
 - drug interactions and, 407
 - functional groups, 67, 110–112, 474
 - Henderson-Hasselbalch equation and, 113–137
 - percent ionization, 124–128
 - therapeutic significance in drug molecules, 89–95
 - using names of salts to identify, 173–174
- active conformation, 294–295
- acyclovir, 26
- acylation, 212, 214–217
- acyl groups, 214
- adenine, 55
- adenosine, 54
 - hydrogen bonds, 235
- adenosine monophosphate (AMP), 364, 419
- adenosine triphosphate (ATP), 364, 470
- adverse drug reactions, 404–407
- aging, 218
- alanine, 50

- albumin, 91, 473
- albuterol, 41–42, 80, 82
oxidation of, 338, 339
- alcohol dehydrogenase (ADH), 317, 337–339
- aldehyde dehydrogenase (ALDH), 317, 337–338
- aldehydes, 7–8
functional group characteristics, 32
oxidative deamination, 328–329
oxidative *N*-dealkylation, 330
phenyl ring with electron withdrawing functional group, 247
reduction of, 345–346
- aldoses, 7–8
- alendronate sodium, 93
- alicyclic amines, 36, 80–82
- alicyclic carbon atoms, oxidation of, 325–326
- alicyclic rings, 39
as hydrophobic, 178
numbering of, 5–6
- alicyclic tertiary amine, 80
- aliphatic amines, 36, 80–82
- aliphatic carbon atoms, oxidation of, 325–326
- aliphatic chains, 39
- aliphatic hydroxyl groups, 77
- aliskiren, 448–451
- alkenes, 39
oxidation of, 321, 322
- alkylating agents, 211–212
- alkylation, 212, 213
- alkyl chains, 39
as hydrophobic, 178
- alkyl group, 31
- alkynes, 39
- allergic rhinitis, 190, 192
- allylic carbon atom, 323
oxidation, 323–324
- α/β designations, 9–11, 12
- α -methyl dopamine α/β designation, 10
- alpha (α) designation, 9–11
- alprostadil, 69
- amantadine, 333
- amides, 32, 88
enol form of, 88
general structure, 49
as hydrogen bond acceptors and donors, 231
hydrolysis of, 349–352
as hydrophilic, 178
oxidation of, 328–337
phenyl ring with electron withdrawing functional group, 247
- amidines, 36, 84–85
as hydrophilic, 178
- amines, 88
- aliphatic and alicyclic, 36, 80–82
- aromatic, 31, 40, 82–83
as hydrogen bond acceptors and donors, 231
oxidation of, 328–337
phenyl rings with electron donating functional groups, 246
- amino acids, 14–17
conjugation, 363–366
functional group present on, 48–53
general structure, 49
ionic bonds, 223
- aminoglutethimide, 324
- aminoglycoside, 93
- amiodarone, 172
- amitriptyline, 286
oxidative *N*-dealkylation, 331, 332
- amlodipine, 451
- amoxicillin, 121
- amphetamine, 329
- amphoteric molecules, 90
- ampicillin, 9, 10, 193
- amprenavir, 468
- amrinone lactate, 167
- analgesic, anti-inflammatory, antipyretic, antithrombotics, 211–212
- anaplastic large cell lymphoma, 432
- angiotensin converting enzyme (ACE), 16–17
structure activity relationships and, 397–399
- angiotensin-converting enzyme (ACE), 251
- angiotensin II receptor blockers (ARBs), 409–410, 422
- anilines, 82–83
as hydrophilic, 178
- annular equivalents, 418
- anomeric carbon, 10
- anomers, 10
- antibacterial drugs, 463–466
- antibiotics, β -lactam, 171
- antihistamines, 403–404, 422–423
- antineoplastic drugs, 470–473
- antipsychotic drugs, 426
- antiviral drugs, 474–476
- arachidonic acid, 250
- arginine, 53, 85, 148
ionic bonds, 223
- aripiprazole, 452–454
- aromatic amines, 31, 82–83
solubility characteristics, 40
sulfate conjugation, 363
- aromatic ether, 31
- aromatic heterocycles, 32
nitrogen containing, 86–87
- aromatic hydroxyl, 31
- aromatic nitrogen atoms, oxidation of, 328–337
- aromatic rings
as hydrophobic, 178
lipid solubility, 39
oxidation of, 318–321
positions, 6
 π - π interactions, 243–247
van der Waals interactions, 239–247
- aromatic thiol, 31
- aryl-aryl stacking interactions, 243–247
- asparagine, 52–53, 228
- aspartic acid, 52, 223–224
- aspirin, 211–212. *See also* salicylic acid
acylation, 215–216
hydrolysis, 349–350
- asthma, 190
- asymmetric carbon atoms, 262–266
- atenolol, 41, 460
oxidative *N*-dealkylation, 331
structure activity relationships and, 395
- atomoxetine, 244–245
glucuronic acid conjugation, 359

oxidative deamination, 329
 atorvastatin, 176
 autism drugs, 452–454
 azo groups, reduction of, 346–348

B

baclofen, 329
 balsalazide, 346
 bases. *See also* acids
 drug interactions and, 407
 functional groups, 67, 79–89, 110–112, 474
 Henderson-Hasselbalch equation and, 113–137
 percent ionization, 124–128
 therapeutic significance in drug molecules, 89–95
 using names of salts to identify, 173–174
 basic functional groups, 67, 79–80, 110–112, 474
 additional nitrogen containing, 87–89
 aliphatic and alicyclic amines, 80–82
 amidines, 36, 84–85
 aromatic amines, 82–83
 defined, 79–80
 guanidines, 36, 84–85, 148–149
 imines and hydrazines, 36, 83–84
 nitrogen containing aromatic heterocycles, 86–87
 beclomethasone dipropionate, 190–191
 benign prostatic hyperplasia (BPH), 288, 298
 structure activity relationships and, 397
 benzimidazole, 246
 benzodiazepines, 83, 182
 benzoic acid, 190
 benzothiazole, 246
 benzoxazole, 246
 benztropine, 233
 benzylic oxidation, 321–324
 β -adrenergic agonists and antagonists, 41, 458–462
 structure activity relationships and, 394–395
 β blockers, 195
 β designation, 9–11
 β -dicarbonyl groups, 36, 69–71
 chelation and, 249–250
 as hydrophilic, 178
 β -glucuronidase, 360
 β -hydroxyl group, 279
 β -lactams
 absorption, distribution, metabolism, and excretion (ADME), 399–404
 as antibiotics, 171, 211–212, 214–215, 391–392
 hydrolysis, 349–352
 mechanism of action, 391–392
 ring, 34, 44, 46
 β -methyl-D-glucose, 265–266
 β -sheet, 236
 beta (β) designation, 9–11
 bethanechol, 123
 bimatoprost, 179, 183
 binding interactions, 209–210
 enhanced, 42–43
 influence of functional groups on, 146–148
 SARs and, 394–399

bioactivation, 428
 bioisosteres, 417–421
 biological targets, 42–43
 concerns with use of covalent bonds and, 211
 ionic bonds and, 222
 local environments and, 225
 bipolar disorder drugs, 452–454
 bisphosphonate, 93
 bonds
 covalent, 209–210, 209–220
 acylation, 212, 214–217
 alkylation, 212, 213
 concerns with use of, 211–212
 defined, 210
 phosphorylation, 213, 218–219
 rearrangement reactions, 213, 219–220
 types of, 212–220
 formation and orbital hybridization of, 4–5
 noncovalent, 209–210, 220–251
 chelation, 248–250
 defined, 220–221
 dipole interactions, 226–237
 hydrogen bonds in, 229–237
 hydrophobic effects, 240–243
 ion-dipole and dipole-dipole interactions, 227–229
 ionic, 146–149, 221–225
 metal complexation, 251
 van der Waals interactions, 221, 237–240
 two types of, 209–210
 brentuximab vedotin, 432
 brimonidine, 85
 brimonidine tartrate, 167
 busulfan, 33
 butorphanol tartrate, 94
 butyrate ester, 190

C

Cahn-Ingold-Prelog system, 272
 candesartan cilexetil, 189
 captopril, 77–78, 251, 341
 methylation, 374
 structure activity relationships and, 398–399
 carbamates, 214
 glucuronic acid conjugation, 359
 as hydrogen bond acceptors and donors, 231
 carbamylation, 214
 carbidopa, 374
 carbinolamine, 330, 429
 carbon atoms
 adjacent to sp^2 hybridized centers, oxidation of, 321–324
 chirality and asymmetric, 262–266
 electronegativity of, 226
 oxidation of aliphatic and alicyclic, 325–326
 carbon-carbon bonds. *See* van der Waals interactions

- carbon-oxygen bonds, oxidation of functional groups with, 337–340
- carbonyl sequence, 15
- carboxylates, 68–69
- carboxylic acids, 68–69, 174
 - functional group characteristics, 14–17, 36
 - glucuronic acid conjugation, 359
 - as hydrogen bond acceptors and donors, 231
 - as hydrophilic, 178
 - in lipid-soluble esters, 190
 - oxidative dehalogenation to, 344
 - structure and nomenclature, 49, 69
- catechol-O-methyltransferase (COMT), 372–375, 374–375
- cefaclor, 400
- cefepime, 171
- cefotaxime, 392
- cefotetan, 405
- cefoxitin, 44, 212, 215, 392
- ceftriaxone sodium, 173
- celecoxib, 73
- cellular biomolecules, oxidation and reaction with, 344
- cephalexin, 46
 - hydrolysis, 350
- cephalosporins, 44, 211
 - absorption, distribution, metabolism, and excretion (ADME), 399
 - acid/base groups, 93
 - drug interactions, 405–406
- cetirizine, 404
- chain branching, 426–428
- chair-chair inversion, 293–294
- chelation, 248–250
 - drug interactions and, 405–406
- chemical antagonism and ionization, 148–149
- chiral centers, designations for, 270–276
- chirality and asymmetric carbon atoms, 262–266
- chlorambucil, 212, 213
- chloramphenicol, 449–450
 - reduction, 348
- chloramphenicol sodium succinate, 188
- chlorpheniramine, 227–228
- chlorpromazine, 409
- chain branching, 426
- chlorpropamide, 411
- chlorprothixene, 408
- cholesterol, 13–14
 - oxidation, 314
- chronic lymphocytic leukemia, 433
- cimetidine, 86–87, 422–423
- ciprofloxacin, 90
- chelation with, 250–251
- cis/trans* configurations, 284–285, 287, 457–458
- citric acid, 174
- classical isosteres, 418–421
- cleavage site, 16
- clindamycin, 233, 411–412, 430
- clindamycin palmitate, 430
- clomiphene citrate, 167
- clonidine hydrochloride, 164
- clopidogrel, 211–212
 - acylation, 219–220
- cocaine, 352
- codeine, 314
- complexation, 251
- conformational isomers, 262, 287–299
 - active, 294–295
 - benefits of restriction of, 295–298
 - defined, 287–288
 - preferred conformation, 291–294
 - terminology, 290–291
- conformational restriction, 408–409
- conjugation, 308, 355–357
 - acetylation, 369–372
 - amino acid, 363–366
 - glucuronic acid, 357–360
 - glutathione, 356, 366–369
 - methylation, 372–375
 - sulfate, 360–363
- covalent bonds, 209–210
 - acylation, 212, 214–217
 - alkylation, 212, 213
 - concerns with use of, 211–212
 - defined, 210
 - phosphorylation, 213, 218–2191
 - rearrangement reactions, 213, 219–220
 - types of, 212–220
- C-terminus, 224
- cyclizine, 403–404
- cyclohexane, 293–294
- cyclohexyl, 39
- cyclooxygenase-1 (COX-1), 42, 215–216, 278
- cyclooxygenase-2 (COX-2), 42, 215–216, 278
- cyclooxygenases (COX), 42–43, 146
 - acylation, 215
 - benefits of conformational restriction in, 297
 - ionic bonds and, 222
 - NSAIDs and, 433
- cyclopentyl, 39
- cyclopentylpropionic acid, 190
- cyclophosphamide, 434
- CYP2D6, 312, 313. *See also* oxidation
- CYP3A4, 312, 469. *See also* oxidation
- CYP450 enzymes, 311–312, 313–316. *See also* oxidation
- cysteine, 52
- cytidine, 54
 - hydrogen bonds, 235
- cytosine, 55

D

- d-Ala-d-Ala sequence, 214, 391
- darunavir, 470
- Debye forces, 237
- deconjugation, 353
- dehalogenation, oxidative, 343–344
- delocalization, resonance, 68, 86
- deoxyribonucleic acid (DNA), 17–18
 - alkylation, 213
 - base pairing, 234
 - functional groups on, 53–55
 - variation of functional groups with, 412–413
- depression drugs, 452–454

- design, drug. See molecular modification
- desmethyldorphine, 45
- dexamethasone, 123
- diaacetolol, 461
- diastereomers, 282–287
 - geometric isomers, 283–286, 449
 - pharmacological and therapeutic differences between geometric isomers and, 287
- diazepam, 83–84
 - drug interactions, 172
 - glucuronic acid conjugation, 360
 - oxidation, 319
 - oxidative *N*-dealkylation, 331
- diclofenac, 42–43, 280–281, 297
 - amino acid conjugation, 366
 - structure activity relationships and, 396
- dicyclomine, 425–426
- dimethyl analog of flurbiprofen inactive, 281
- dipeptides, 14–17
- diphenhydramine, 403–404
- diphenoxylate, 351
- dipole-dipole interactions, 227–229
- dipole interactions, 226–237
 - hydrogen bonds in, 229–237
 - ion-dipole and dipole-dipole interactions, 227–229
- displaced interactions, 243
- dissociation constants, 220–221
- disubstituted amides, 231
- disubstituted carbamates, 231
- D/L designations, 12
- d/l* designations, 11
- donors, hydrogen bond, 37–38, 53, 230–231
- dopamine
 - α/β designation, 10
 - methylation, 373
- dosing, 43, 211
- double bonds, 5
- doxepin, 285–286
- doxycycline, 46–47
 - absorption, distribution, metabolism, and excretion (ADME), 401–402
- drug binding interactions. See binding interactions
- drug design. See molecular modification
- drug interactions. See interactions
- drug metabolism. See metabolism
- duloxetine, 345–346

E

- E*-chlorprothixene, 409
- edge-to-face interactions, 243
- E* isomers, 408–409
- electron donating functional groups, 30–31, 246
 - chelation and, 248–250
- electronegativity, 29, 226
- electronic effects of functional groups, 27–35
- electron withdrawing functional groups, 31, 72, 247
 - SAR statements “why” or “how” components, 389–390
- electrophilic functional groups, 32–35
- electrophilic intermediates, 363
- enalaprilat, 16–17, 268–269
 - structure activity relationships and, 398–399
- enantiomers, 11, 267–269, 466
 - chemical and physical properties of, 269–270
 - compared to diastereomers, 282–283
 - designations for chiral centers and, 270–276
 - pharmacological and therapeutic differences between, 276–281
- encainide, 335
- enterohepatic circulation, 360
- enterohepatic recycling, 194, 353, 360
- environment, calculating the pH of, 128–129
- epinephrine, 459
 - methylation, 372–373
 - structure activity relationships and, 394
- epirubicin, 354
- eprosartan, 409–410
- eptifibatid, 348
- erythromycin stearate, 169–170
- esmolol, 462
 - hydrolysis, 350
- esters
 - carboxylic acids used to prepare lipid-soluble, 190
 - converting parent drug molecules to prodrug, 187–191
 - functional group characteristics, 32
 - as hydrogen bond acceptors, 231
 - hydrolysis of, 349–352
 - as hydrophilic, 178
 - ionic bonds, 222
 - prodrug, 428–431
 - similarities with organic salts, 170
 - solubility characteristics, 39
- estradiol, 14, 76–77
 - absorption, distribution, metabolism, and excretion (ADME), 401
- estradiol valerate, 189–190
- estrogen replacement therapy, 189
- estrone, 180, 362
- estrone sodium sulfate, 79
- estrone sulfate, 354
- ethers, 32
 - as hydrogen bond acceptors, 231
 - as hydrophilic, 178
 - solubility characteristics, 40
- ethinyl estradiol, 323, 457
 - absorption, distribution, metabolism, and excretion (ADME), 401
- ethylenediaminetetraacetic acid (EDTA), 248–249
- etidronate disodium, 173
- ezetimibe, 228, 233

F

- face-to-face interactions, 243
- fenofibrate, 188
- fenopropfen, 42–43, 297
 - oxidation, 314, 319
- fexofenadine, 404
- first-pass metabolism, 312
- Fisher projection, 271

5 α -dihydrotestosterone, 14
 flavin monooxygenase (FMO) enzymes, 317
 flipping, 293–294
 fluconazole, 406
 fluocinolone acetonide, 192
 fluorine, 177, 230–231
 fluoroquinolones, 463–466
 chelation with, 250
 drug interactions and, 405
 fluoxetine, 22–23, 339
 flurazepam, 324
 fluvastatin, 176, 393
 fluvoxamine, 359
 formaldehyde, 434–435
 fosamprenavir, 354
 fosamprenavir calcium, 79, 468
 fosphenytoin, 430
 free base, 140
 frovatriptan, 86–87
 fructose, 7–8
 fumaric acid, 174
 functional groups, 21
 acid, 67, 68–79, 110–112, 474
 added or altered for affect solubility, 191–193
 on amino acids, 48–53
 basic, 67, 79–89, 110–112, 474
 calculating the pK_a of, 129–130
 with carbon-oxygen bonds, oxidation of, 337–340
 chemical properties of, 26–44
 defined, 22–26
 on DNA and RNA, 53–55
 electron donating and withdrawing, 30–31, 246–250, 389–390
 electronic effects of, 27–35
 hydrophilic, 35–38, 176–179
 hydrophobic, 38–40, 176–179
 lipophilic, 38–40, 176–179
 lipophobic, 176
 molecular modification variation of, 409–414
 percent ionization of, 124–128
 pH and pK_a of, 107–109
 role of, 23–24
 solubility effects, 35–40
 steric effects, 40–44
 structure of, 389
 furan, 246
 furosemide, 235

G

gabapentin, 80, 82
 gastroesophageal reflux disease (GERD), 236, 263, 435
 gauche conformations, 291–292, 294
 gentamicin, 93, 171
 geometric isomers, 283–286, 449
 pharmacological and therapeutic differences between diastereomers and, 287
 glaucoma, 218
 glipizide, 73
 glucocorticoids, 190–192

glucose, 7–8
 glucuronic acid, 308
 conjugation, 357–360
 glucuronide conjugate of morphine, 354
 glutamic acid, 52, 224–225
 glutamine, 52–53
 glutathione, 33, 308, 356
 conjugation, 356, 366–369
 oxidation, 320
 glyburide, 323
 glycine, 50, 367–368
 glycosidic bonds, 12–13
 Grimm's Hydride Displacement Law, 414–415
 guanidines, 36, 84–85, 148–149
 as hydrophilic, 178
 guanine, 33, 55
 guanosine, 54
 hydrogen bonds, 235
 guanosine monophosphate (GMP), 419–420

H

halcinonide, 192
 halogens, 31–32
 electronegativity, 226
 as hydrophobic, 178
 lipid solubility, 39
 phenyl ring with electron withdrawing functional group, 247
 haloperidol, 172
 haloperidol decanoate, 189–191
 Henderson-Hasselbalch equation, 105–106, 109–112
 calculating percent ionization using, 124–128
 calculating pH of an environment using, 128–129
 qualitative problems not using, 116–122
 qualitative problems using, 113–123
 quantitative problems, 113, 124–137
 Rule of Nines and, 124, 131–137
 heparin, 149, 173
 drug interactions, 172
 functional groups, 179–180
 heterocyclic nitrogens, 36
 as hydrogen bond acceptors, 231
 as hydrogen bond donors, 231
 heterocyclic rings, 246–247
 numbering, 7
 histidine, 16, 53
 ionic bonds, 223
 HIV protease inhibitors, 463–466
 Hodgkin lymphoma, 432
 Hodgkin's disease, 213, 266, 433
 homocysteine, 52
 homologation, 423–426
 hybridization, orbital, 4–5
 hydralazine, 359
 acetylation, 370
 hydrazines, 36, 83–84
 glucuronic acid conjugation, 359
 hydrobromic acid, 173
 hydrocarbon rings and chains, oxidation of, 318–327

- alkenes, 321, 322
- aromatic rings/aromatic hydroxylation, 318–321
- hydrochloride (HCl) salt, 140, 173
- hydrochlorothiazide, 150
- hydrocortisone, 190–191
- hydrogen atoms, electronegativity of, 226
- hydrogen bonds
 - in dipole interactions, 229–237
 - disadvantages of, 236–237
 - donors and acceptors, 37–38, 53, 230–231
- hydrolysis, 349–355, 429
 - prodrug, 431
- hydrophilic functional groups, 35–38, 176–179
- hydrophobic functional groups, 38–40, 176–179
- hydroxylamines, 334–335
 - glutathione conjugation, 368
 - sulfate conjugation, 363
- hydroxylation, 318–321
- hydroxyl groups, 32, 178
 - absorption, distribution, metabolism, and excretion (ADME), 401–402
 - glucuronic acid conjugation, 359
 - as hydrogen bond acceptor and donor, 231
 - oxidation of, 337–340
 - phenyl rings with electron donating functional groups, 246
- hypertension drugs
 - angiotensin-converting enzyme (ACE), 251
 - β -adrenergic receptor antagonist, 458–462
 - renin inhibitor, 448–451
 - structure activity relationships and, 396
 - sulfate conjugation, 362
- hypoxanthine, 420
- organic salts and, 171–172
- plasma protein binding, 91, 144–145, 407
- plasma protein displacement, 91
- structure activity relationships and, 404–407
- interferon alfa-2a and 2b, 431
- intrinsic inductive character, 29
- ion-dipole interactions, 227–229
- ionic bonds, 146–148, 221–225
 - chemical antagonism and, 148–149
 - reinforced, 235
- ionization
 - duration of action of drug molecules and, 144–146
 - influence on drug binding interactions, 146–148
 - water solubility and, 139–143
- ionized acidic group, 31
- ionized basic group, 32
- irbesartan, 75, 267–268, 409–410
 - glucuronic acid conjugation, 359
- isavuconazole, 431–432
- isavuconazonium sulfate, 431–432
- isofluorophosphate, 218–219
- isoleucine, 50
- isomers, conformational. *See* conformational isomers
- isoniazid, 371
- isoproterenol, 234, 395
 - structure activity relationships and, 394
- isosorbide mononitrate, 77
- isosteres, 414–417
 - classical, 418–421
 - nonclassical, 421–423
- isosteres, 74
- isoxazole, 86

I

- ibandronate sodium, 93
- ibuprofen
 - α/β designation, 9–10
 - carboxylic acid, 69
 - ionic bonds, 222
 - overview, 1–2
 - oxidation of, 326
- imidazole ring, 36, 86, 246
 - drug interactions and, 406
- imide, 36, 69, 88
- imines, 36, 83–84
- imipramine, 83
- indole, 86, 246
- indomethacin, 25, 360
- influenza A and B, 474–476
- inorganic salts, 163–166
 - for enhancing water or lipid solubility, 186
- inosine monophosphate (IMP), 420
- insulin, 348
- interactions, 149–152
 - binding, 209–210
 - enhanced, 42–43
 - influence of functional groups on, 146–148
 - SARs and, 394–399

K

- Keesom forces, 227, 237
- ketoconazole, 406
- ketones, 7–8
 - as hydrogen bond acceptors, 231
 - oxidative deamination, 328–329
 - phenyl ring with electron withdrawing functional group, 247
 - reduction of, 345–346
- ketoprofen, 318
 - oxidation, 319
- ketorolac tromethamine, 166
- ketoses, 7–8

L

- labetalol, 362
- lactams. *See* β -lactams
- lactones, 181
 - hydrolysis of, 349–352
 - metabolite of niacin, 333
- leucine, 50
- leucovorin calcium, 173

levonorgestrel, 454–458
 levothyroxine, 76–77, 145–146
 lidocaine, 80, 82, 92
 chain branching, 427–428
 hydrolysis, 350, 353
 metabolism of, 310
 lincomycin, 411–412
 liothyronine, 76–77, 145–146
 lipid-solubility. *See also* solubility; water-solubility
 adding or altering functional groups for, 191–193
 advantages of enhancing, 197
 analyzing drug molecules for, 176–179
 antihistamine sedation and, 403–404
 aripiprazole, 452
 balance between water and, 184–186
 converting parent drug molecules to ester prodrug and, 187–191
 drug interactions and, 406
 enterohepatic recycling and, 194
 functional groups, 38–40
 influence on drug metabolism, 193–196
 inorganic and organic salts and, 186
 metabolism and, 309
 organic salts, 167–170
 prodrug esters, 428–429
 strategies for optimizing the desired, 186–193
 lipophilic functional groups, 38–40, 176–179
 lipophobic functional groups, 176
 lomustine, 266
 London dispersion forces, 237
 losartan, 237–238, 452–453
 oxidation of, 326
 losartan potassium, 164
 lovastatin, 26, 176
 lysine, 53
 ionic bonds, 223

M

magnesium, 250
 mania drugs, 452–454
 mechlorethamine, 433, 434
 medicinal chemistry
 acid/base nature of drug molecules in, 89–95
 definition of, 1
 drug interactions in, 149–152, 171–172
 drug metabolism in, 43–44, 193–196
 functional groups role in, 23–24
 importance of pH and pK_a in, 137–152
 review of selected nomenclature and numbering in, 4–17
 mefenamic acid, 396
 meperidine, 92
 oxidative *N*-dealkylation, 331
 van der Waals interactions, 239, 242
 meprobamate, 359
 metabolism
 alteration of, 43–44
 conjugation, 308, 355–357
 acetylation, 369–372
 amino acid, 363–366

 glucuronic acid, 357–360
 glutathione, 356, 366–369
 methylation, 372–375
 sulfate, 360–363
 enantiomers, 281
 factors that affect, 311–312, 376
 general concepts of, 309–312
 hydrolysis, 349–355
 influence of solubility in, 193–196
 oxidation
 aliphatic and alicyclic carbon atoms, 325–326
 alkenes, 321, 322
 amines, amides, and aromatic nitrogen atoms, 328–337
 aromatic rings/aromatic hydroxylation, 318–321
 carbon atoms adjacent to sp^2 hybridized centers, 321–324
 cytochrome P450 family of enzymes in, 313–316
 functional groups containing sulfur atoms, 340–343
 functional groups with carbon-oxygen bonds, 337–340
 hydrocarbon rings and chains, 318–327
 N-, 333–337
 other enzymes involved in oxidative transformations, 317–318
 oxidative deamination, 328–329
 oxidative dehalogenation, 343–344
 oxidative *N*-dealkylation, 329–333
 oxidative transformation, 317–318, 449
 phases of, 307–308
 reduction, 313
 aldehydes and ketones, 345–346
 azo and nitro groups, 346–348
 miscellaneous, 348–349
 xenobiotic, 315–316
 meta designation, 6
 methylation at, 374
 oxidation at, 318, 327
 metal complexation, 251
 metaproterenol, 394
 metformin, 85
 methacholine, 26
 metabolism alteration, 43–44
 methadone, 347
 methdilazine, 427
 methenamine, 434–435
 methotrexate, 143
 methoxy, 246
 methyl α -D-glucopyranoside, 11, 12–13
 methylation, 372–375
 methyl β -D-glucopyranoside, 11, 12–13
 methylene groups, homologation using, 423–426
 methyl phenyl rings with electron donating functional groups, 246

methylsalicylate, 147
 methyltestosterone, 45, 401
 methyl-tetrazole-thiomethyl (MTT) group, 405
 metamide, 423
 metoclopramide, 236
 metoprolol, 263–264
 metronidazole, 348
 minoxidil, 362
 mitoxantrone, 244
 mixed-function oxidases, 313
 molecular modification

- bioisosteres in, 417–421
- chain branching, 426–428
- conformational restriction, 408–409
- conversion of active drug to prodrug, 428–436
- defined, 407–408
- homologation, 423–426
- isosteres in, 414–423
- variation of functional groups, 409–414

 monomethoxy PEG, 431
 monomethylauristatin E (MMAE), 432
 morphine, 45

- glucuronic acid conjugation, 360
- homologation of, 424–425
- hydrogen bonds, 233
- hydrolysis of, 354

 morphine sulfate, 164
 mutarotation, 10
 myasthenia gravis, 296

N

N-(3-acetoxypentyl)-N-methylamino-carboxymethyl prodrug, 431
 nabumetone, 433–434
 N-acetylsialic acid, 474
 N-acetyltransferase (NAT), 370–372
 nadolol, 458–462
 naphazoline, 84–85
 naproxen

- α/β designation, 9–10
- overview, 1–2
- as salt, 164–165

 naproxen sodium, 164–165
 nateglinide, 359
 N-dealkylation, oxidative, 329–333, 429
 nefazodone, 247
 neostigmine, 216–217

- hydrolysis of, 354

 neostigmine bromide, 296
 Newman projections, 290–291
 niacin, 333
 nicardipine, 331
 nicotinamide adenine dinucleotide (NAD⁺), 317–318
 nifedipine, 396
 nilotinib, 472–473
 nimodipine, 372
 nitrile group, 32, 247
 nitro, 247
 nitrofurantoin, 348
 nitrogen, 15

- additional functional groups containing, 87–89

in amidines and guanidines, 36, 84–85
 atoms, oxidation of aromatic, 328–337
 in β -dicarbonyl groups, 69–71
 common functional groups, 36
 containing aromatic heterocycles, 86–87
 as hydrogen bond acceptors, 231
 as hydrogen bond donor, 230
 nitro groups, 32

- reduction of, 346–348

 nizatidine, 423
 N-methyl dopamine, 280
 N-methyltransferase, 372–375
 nonclassical isosteres, 421–423
 noncovalent bonds, 209–210

- chelation, 248–250
- defined, 220–221
- dipole interactions, 226–237
- hydrogen bonds in, 229–237
- hydrophobic effects, 240–243
- ion-dipole and dipole-dipole interactions, 227–229
- ionic, 146–149, 221–225
- metal complexation, 251
- van der Waals interactions, 221, 237–240

 nonelectrolytes, 90
 non-Hodgkin's lymphoma, 213
 non-sedating antihistamines, 403–404
 non-steroidal anti-inflammatory drugs (NSAIDs), 42

- acylation, 215–216
- benefits of conformational restriction in, 297–298
- ionic bonds, 222
- α -methyl acetic acid subclass, 280
- prodrugs and, 433
- reduction of, 349
- structure activity relationships and, 396–397
- as water-soluble organic salt, 166

 norethindrone, 362
 N-oxidation, 333–337
 N-terminus, 223, 224
 nucleic acid nomenclature, 17–18
 nucleophilic functional groups, 32–35
 nucleosides, 17–18

O

octapeptides, 15–16
 ofloxacin, 463–466

- drug interactions, 405–406

 omega (ω) designation, 9–11
 omeprazole, 263, 434, 435–436
 oral absorption and drug metabolism, 194
 oral contraceptives, 360, 454–458
 orbital hybridization and bond formation, 4–5
 organic salts, 163

- drug interactions and, 171–172
- for enhancing water or lipid solubility, 186
- lipid-soluble, 167–170
- similarities with esters, 170
- water-soluble, 166–167

 orphenadrine, 426
 ortho designation, 6

in hydrophilic and hydrophobic drug molecules, 180–181
 oxidation at, 318, 321
 resonance and, 28
 steric hindrance and, 46
 structure activity relationships and, 395–396

oseltamivir, 474–476
 hydrolysis, 351

oxacillin, 392

oxazole, 246

oxidation
 of aliphatic and alicyclic carbon atoms, 325–326
 of alkenes, 321, 322
 of amines, amides, and aromatic nitrogen atoms, 328–337
 of aromatic rings/aromatic hydroxylation, 318–321
 of carbon atoms adjacent to sp^2 hybridized centers, 321–324
 cytochrome P450 family of enzymes in, 313–316
 of functional groups containing sulfur atoms, 340–343
 of functional groups with carbon-oxygen bonds, 337–340
 of hydrocarbon rings and chains, 318–327
 N-, 333–337
 other enzymes involved in oxidative transformations, 317–318
 oxidative deamination, 328–329
 oxidative dehalogenation, 343–344
 oxidative N-dealkylation, 329–333, 429
 oxidative transformation, 317–318, 449

oxidative deamination, 328–329

oxidative dehalogenation, 343–344

oxidative N-dealkylation, 329–333, 429

oxidative transformation, 317–318, 449

oxygen as hydrogen bond donor, 230

oxyphenbutazone, 70

P

p450 monooxygenase enzymes, 311

pamidronate disodium, 79

para-aminobenzoic acid (PABA), 147–148, 390–391
 variation of functional groups with, 413

para designation, 6
 amoxicillin, 193
 oxidation at, 318
 resonance and, 28

para methyl substituents, 410–411

paroxetine, 319

partition coefficients, 175–176
 in analyzing drug molecules for water- and lipid-soluble components, 176–179

passive diffusion, 473

passive reabsorption, 144

pegylated interferons, 431

pemirolast potassium, 173

penicillamine, 77–78, 248

penicillin G, 186, 189
 α/β designation, 9–10
 absorption, distribution, metabolism, and excretion (ADME), 400
 as lipid-soluble organic salt, 94, 168, 186
 as naturally occurring, 33–35

penicillins, 9, 10
 absorption, distribution, metabolism, and excretion (ADME), 399–404
 acid/base groups, 93, 94
 electron donating or withdrawing functional group, 33–35
 as salts, 162–164

penicillin V, 46, 69, 173
 absorption, distribution, metabolism, and excretion (ADME), 399–400
 as acidic drug molecule, 162–163
 as naturally occurring, 33–35

penicillin V potassium, 173

pentazocine, 325
 glucuronic acid conjugation, 360
 methylation, 374

pentobarbital, 326, 339, 343

peptic ulcer disease, 140

peptide designations, 14–17

percent ionization of functional group, 124–128

perindopril, 351

pH, 105–106
 defining, 106–109
 drug interactions based on changes in, 149–152
 of environment, calculating, 128–129
 Henderson-Hasselbalch equation and, 105–106, 109–112
 importance in drug therapy, 137–152
 influence on duration of action for drug molecules, 144–146
 influence on solubility of drug molecules, 139–143
 ionic bonds, 223–224
 partition coefficients and, 175
 percent ionization of functional group and, 124–128
 qualitative problems, 113–123
 Rule of Nines and, 124, 131–137
 solving problems of, 113–137

pharmacodynamics effects, 23

pharmacokinetic effects, 23

phase II metabolism, 307–310. *See also* metabolism
 conjugation, 355–375
 summary of, 375

phase I metabolism, 307–310. *See also* metabolism
 hydrolysis, 349–355
 oxidation (*See* oxidation)
 reduction, 313, 345–349
 summary of, 355

phenobarbital, 144
 acid/base groups, 70, 92

phenol-O-methyltransferase (POMT), 372–375

phenols, 75–77
 functional group characteristics, 31, 36
 glucuronic acid conjugation, 359
 as hydrogen bond acceptors and donors, 231
 as hydrophilic, 177–178
 intrinsic inductive character of, 30

- oxidation, 319–320
 resonance in, 28
 solubility characteristics, 40
 sulfate conjugation, 361–362
 in thyroid hormones, 145
 phenothiazines, 426
 phenylalanine, 16, 50–51
 π - π interactions, 243
 van der Waals interactions, 239
 phenylephrine, 321
 phenylpropanolamine, 374
 phenytoin, 70, 263–264, 429–430
 phenytoin sodium, 164
 Philadelphia Chromosome (Ph⁺) positive chronic
 myelogenous leukemia, 472
 phosphates, 17–18, 78–79
 phosphonates, 78–79
 phosphonic acid, 36
 phosphorylation, 213, 218–219
 phosphoserine, 51
 phytonadione, 179
 pindolol, 92
 oxidation, 314
 pioglitazone, 359
 piroxicam, 70
 pitavastatin, 176
 pivalic acid, 190
 p*K*_a, 105–106
 in acidic functional groups, 68, 88–89
 in basic functional groups, 79–80, 88–89
 chemical antagonism and, 148–149
 defining, 106–109
 drug interactions based on changes in,
 149–152
 of functional group, calculating, 129–130
 Henderson-Hasselbalch equation and,
 105–106, 109–112
 importance in drug therapy, 137–152
 influence on duration of action for drug
 molecules, 144–146
 influence on solubility of drug molecules,
 139–143
 ionic bonds, 223–224
 percent ionization of functional group and,
 124–128
 qualitative problems, 113–123
 Rule of Nines and, 124, 131–137
 solving problems of, 113–137
 plasma protein binding interactions, 91, 144–145,
 407
 plasma protein displacement interactions, 91
 (+)/(-) designations, 11, 271–276
 polyethylene glycol (PEG) prodrugs, 431
 potassium penicillin, 162
 π - π interactions, 243–247
 pralidoxime chloride (2-PAM), 218–219
 pravastatin, 176, 181, 393
 prazosin, 87, 288, 290, 298
 structure activity relationships and, 397
 prednisolone sodium phosphate, 188
 preferred conformation, 291–294
 presystemic metabolism, 312
 primaquine, 334
 primary amines
 aliphatic, 36, 80–82
 aromatic, 36
 glucuronic acid conjugation, 359
 as hydrophilic, 178
 N-oxidation, 333–334
 oxidative deamination, 328–329
 probenecid, 69, 366
 procainamide, 83
 acetylation of, 370–371
 hydrolysis of, 353
 isosteric replacement, 419
 procaine, 419
 prochlorperazine, 336
 prodrugs, 187–191
 conversion of active drugs to, 428–436
 hydrolysis, 349–352
 metabolism of, 311
 products of reactions, 163
 proline, 50
 promethazine, 172
 chain branching, 427
 prontosil, 140–141
 propanteline, 425–426
 propionic acid, 190
 propranolol, 195
 propylthiouracil, 359
 prostaglandins, 179, 433
 protamine, 148–149
 protriptyline, 322
 pteridine, 247
 purines
 on DNA and RNA, 54–55
 nucleic acid nomenclature, 17–18
 ring numbering, 7
 pyrazine, 247
 pyridazine, 247
 pyridine, 86, 247
 pyridostigmine bromide, 296
 pyrimidine, 247
 on DNA and RNA, 54–55
 nucleic acid nomenclature, 17–18
 ring numbering, 7
 pyrrole ring, 86, 231, 246
-
- Q**
 qualitative problems, 113–123
 quantitative problems, 113, 124–137
 quaternary ammonium group, 88
 quazepam, 182
 metabolism, 195–196
 oxidation of, 343
 quinazoline, 247, 288, 290
 quinidine, 87
 quinoline ring, 36, 86, 247
-
- R**
R-(-)-albuterol, 278
 raloxifene, 360

ramiprilat, 251
 ranitidine, 340–342, 423
R-disopyramide, 278
 rearrangement reactions, 213, 219–220
 reduction, 313
 of aldehydes and ketones, 345–346
 of azo and nitro groups, 346–348
 miscellaneous, 348–349
 reinforced ionic bonds, 235
 renal elimination, 144–146
R-(-)-epinephrine, 280
 resonance, 27–28
 resonance delocalization, 68, 86
R-flurbiprofen, 280–281
 ribonucleic acid (RNA), 17–18
 functional groups on, 53–55
 variation of functional groups with, 412–413
 zileuton and, 249
 ribose, 7–8
 rilpivirine, 312
 ritonavir, 469
 rizatriptan, 365–366
R-methacholine, 278
 rosuvastatin, 176
R/S designations, 12, 270–276
 pharmacological and therapeutic differences
 between enantiomers with, 276–281
 Rule of Nines, 124, 131–137
 carboxylic acid of PABA approximation, 148
 uric acid approximation, 143

S

S-adenosylhomocysteine, 373
S-adenosylmethionine, 373
S- (+)-albuterol, 278
 salicylic acid, 146–147. *See also* aspirin
 acid/base groups, 92
 amino acid conjugation, 364–365
 salmeterol, 239–240
 oxidative *N*-dealkylation, 331
 salts, 94–95, 161–162
 application to drug molecules, 162–163
 defined, 162–163
 for enhancing water or lipid solubility, 186
 identifying acidic and basic drug molecules
 using names of, 173–174
 inorganic, 163–166
 organic, 163, 166–172
 saquinavir, 467–470
 schizophrenia drugs, 452–454
S-disopyramide, 278
 secondary amines, 178
 aliphatic, 36, 80–82
 glucuronic acid conjugation, 359
 N-oxidation, 334–335
 oxidative deamination, 328–329
 oxidative *N*-dealkylation, 329–333
 secondary hydroxyl, 359
 sedating antihistamines, 403–404
 selectivity, 41–42
S- (+)-epinephrine, 280

serine, 51–52
 serotonin, 22
S-flurbiprofen, 280–281
 simvastatin, 26, 176, 181, 393
 hydrolysis, 350
 single bonds, 5
 6-mercaptopurine, 420
S-ketoprofen, 278
S-methacholine, 278
S-methyltransferase, 372–375
S-naproxen, 278
 sodium bicarbonate, 142, 149–150
 sodium hydroxide, 173
 sodium sulfacetamide, 94
 solubility. *See also* lipid-solubility; water-solubility
 adding or altering functional groups for,
 191–193
 advantages of enhancing water or lipid, 197
 analyzing drug molecules for, 176–179
 balance between water and lipid, 184–186
 converting parent drug molecules to ester
 prodrug and, 187–191
 functional groups and, 35–40
 important skills to master with, 179–183
 influence on drug metabolism, 193–196
 ionization and, 139–143
 and partition coefficients, 175–186
 strategies for optimizing the desired water or lipid,
 186–193
 sorafenib, 470–473
 sp² hybridized centers, 321–324
 spironolactone, 324
 stereochemical designations, 11–13
 stereochemistry, 261–262
 chirality and asymmetric carbon atoms,
 262–266
 conformational isomers, 287–299
 designations, 11–13
 diastereomers, 282–287, 449
 enantiomers, 11, 267–269
 designations for chiral centers
 and, 270–276
 pharmacological and therapeutic
 differences between, 276–281
 pharmacological and therapeutic
 differences between geometric
 isomers and diastereomers, 287
 stereoisomers, 261–262
 steric effects, 40–44, 46
 hydrolysis, 352
 noncovalent bonds and, 221
 steroid nomenclature, 13–14
 structure activity relationships (SAR), 387
 absorption, distribution, metabolism, and
 excretion (ADME) and, 399–404
 binding interactions and, 394–399
 drug interactions and adverse drug reactions
 and, 404–407
 examples of, 390–407
 overview of, 388–389
 pharmacological activity and, 390–393
 “why” or “how” component of SAR state-
 ments, 389–390
 sugars numbering, 7–8

sulfacetamide, 72, 73
 acid/base groups, 94
 sulfamethoxazole, 86–87, 142, 148
 acetylation, 371
 SAR statements “why” or “how” components, 389–390
 sulfate conjugation, 362
 sulfanilamide, 73, 141–142, 148
 SAR statements “why” or “how” components, 389
 sulfate conjugation, 360–363
 sulfates, 78–79
 sulphydryl, 32
 glucuronic acid conjugation, 359
 sulfisoxazole, 73, 391
 glucuronic acid conjugation, 359
 sulfisoxazole acetyl, 74
 sulfisoxazole diolamine, 167
 sulfonamides, 71–74, 88
 functional group characteristics, 32, 36, 130
 as hydrophilic, 178
 sulfonylurea, 71–74, 73
 variation of functional groups with, 410–411
 sulfotransferase (SULT), 361
 sulfoxides, 342
 reduction of, 348–349
 sulfur, 226
 as hydrogen bond donor, 230
 oxidation of functional groups containing, 340–343
 sulindac, 349
 sumatriptan, 72, 73

T

tamoxifen, 239–240, 285–286
 oxidation of, 322, 324
 tamsulosin, 288–289, 298
 structure activity relationships and, 397
 tautomeric forms, 71
 t-butylacetic acid, 190
 telmisartan, 409–410
 temazepam, 182
 metabolism of, 195–196, 310
 terbutaline, 394
 tertiary amines, 88, 125
 aliphatic, 36, 80–82
 aromatic, 82–83
 as hydrophilic, 178
 oxidative N-dealkylation, 329–333
 testosterone, 14, 45
 absorption, distribution, metabolism, and excretion (ADME), 401
 tetracaine, 372
 tetracyclines, 46–47
 absorption, distribution, metabolism, and excretion (ADME), 401–402
 chelation with, 249–250
 drug interactions, 405–406
 water solubility of, 309
 tetrahydrozoline, 84–85
 tetrazoles, 74–75, 409–410

glucuronic acid conjugation, 359
 thiazide diuretics, 149–150
 acid/base groups, 93
 thienopyridine antithrombotics, 211–212, 219–220
 thiethylperazine, 340–342
 thiocarbonyl, 342–343
 thioethers as hydrogen bond acceptors, 231
 thio-inosine monophosphate (T-IMP), 420
 thiol, 32
 as hydrogen bond acceptor and donor, 231
 thiols, 77–78
 thiopental, 343
 thiophene, 246
 thiophenol, 78
 thioridazine, 163
 thioridazine hydrochloride, 163
 thiothixene, 408
 3-hydroxy-3-methylglutaryl CoA (HMG-CoA), 392–393
 3'-phosphoadenosine-5'-phosphosulfate (PAPS), 360–361
 threonine, 51–52, 228
 thymidine, 54
 hydrogen bonds, 235
 thymine, 55
 thyroid hormones, 76–77, 145–146, 360
 ticlopidine, 80, 82
 timolol maleate, 167, 191
 tirofiban, 72, 73
 tobramycin, 93
 functional groups, 179–180
 metabolism, 195
 tocainide, 427–428
 tolbutamide, 452–453
 oxidation, 314
 variation of functional groups with, 410–411
 tolmetin, 338
 tolterodine, 244
 trans conformations, 291–292
 transpeptidase, 214–215
 triamcinolone, 192
 trientine, 248
 trifluoperazine, 427
 trifluoromethyl groups, 31–32, 183
 oxidative dehalogenation, 449
 trimethadione, 70
 trimethyllysine, 53
 tripeptides, 14–17
 triple bonds, 5
 tromethamine salt, 166
 tryptophan, 51, 247
 T-shaped interactions, 243
 2-oxoclopidogrel, 219–220
 tyrosine, 16, 51–52

U

UDP-glucuronic acid (UDPGA), 357–359
 UDP-glucuronyltransferase (UGT), 357–359
 ulcers, gastric and duodenal, 435
 γ -glutamate, 366–369
 uracil, 55

urea as hydrogen bond acceptors and donors, 231
uric acid, 143
uridine, 54

V

valacyclovir, 351
valeric acid, 190
valine, 16, 50
valsartan, 75
van der Waals interactions, 221, 237–240
 hydrophobic effects, 240–243
 π - π interactions, 243–247
vascular endothelin growth factor 2 (VEGF2), 470
verapamil, 140
vitamin K₁, 179–180

W

warfarin
 acid/base groups, 70, 92
 chiral center, 267
 ketone reduction, 347
water-solubility. *See also* lipid-solubility; solubility
 adding or altering functional groups for, 191–193
 advantages of enhancing, 197
 analyzing drug molecules for, 176–179
 aripiprazole, 452
 balance between lipid and, 184–186
 converting parent drug molecules to ester prodrug and, 187–191
 drug interactions and, 406
 functional groups, 35–38
 influence on drug metabolism, 193–196
 inorganic and organic salts and, 186
 metabolism and, 309
 organic salts, 166–167
 prodrug esters, 428–431
 strategies for optimizing the desired, 186–193
whole molecule drug evaluation, 447
 aliskiren, 448–451
 aripiprazole, 452–454
 levonorgestrel, 454–458
 nadolol, 458–462
 ofloxacin, 463–466
 saquinavir and other HIV protease inhibitors, 463–466
 sorafenib, 470–473
 zanamivir and oseltamivir, 474–476
Wilson's disease, 248

X

xenobiotic metabolism, 315–316

Z

zafirlukast, 72, 73
zaleplon, 336
zanamivir, 474–476
 metabolism, 195
Z-chlorprothixene, 409
zidovudine, 412–414
zileuton, 249–250
Z isomers, 408–409
Z-thiothixene, 409
zwitterion form, 193